Neuroendocrine tumors of the lung include the small cell carcinoma (SCLC), and large cell
neuroendocrine carcinoma (LCNEC) and represent 20% of lung cancer. One of the only studies
reported to date is reporting on a progression-free survival (PFS) and overall survival (OS)
of 5.2 months and 7.7 months, respectively.
Poorly differentiated gastroentero-pancreatic neuroendocrine carcinomas (GEP-NEC) represent a
small sub-group of digestive NENs, according to the studies, 7 to 21% of patients. However,
their prognosis is more negative, with the 5-year survival at less than 20%.
Many Phase III trials showed superiority in terms of efficacy and tolerance of
nivolumab+/-ipilimumab versus standard chemotherapy in second-line treatment in metastatic
solid tumors. Neuroendocrine tumors are considered as rare disease without therapeutic
guidelines in this setting. The French academic oncology groups (IFCT, FFCD and GERCOR) have
the opportunity to recruit a sufficient number of patients, in a reasonable period of time,
to provide a proof-of-concept of the safety and efficacy of nivolumab+/-ipilimumab in this
Clinical Study Identifier
Intergroupe Francophone de Cancerologie Thoracique
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.